CL2022000329A1 - Agentes antipalúdicos. - Google Patents

Agentes antipalúdicos.

Info

Publication number
CL2022000329A1
CL2022000329A1 CL2022000329A CL2022000329A CL2022000329A1 CL 2022000329 A1 CL2022000329 A1 CL 2022000329A1 CL 2022000329 A CL2022000329 A CL 2022000329A CL 2022000329 A CL2022000329 A CL 2022000329A CL 2022000329 A1 CL2022000329 A1 CL 2022000329A1
Authority
CL
Chile
Prior art keywords
plasmepsin
compounds
treatment
administration
formula
Prior art date
Application number
CL2022000329A
Other languages
English (en)
Inventor
John A Mccauley
Alan F Cowman
Lera Ruiz Manuel De
Paola Favuzza
Zhuyan Guo
Bin Hu
Iii Michael J Kelly
Zhiyu Lei
David B Olsen
Brad Sleebs
Jennifer K Thompson
Tony Triglia
Dongmei Zhan
Cailing Zhang
Lianyun Zhao
Original Assignee
Merck Sharp & Dohme
Walter & Eliza Hall Inst Medical Res
Msd R&D China Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme, Walter & Eliza Hall Inst Medical Res, Msd R&D China Co Ltd filed Critical Merck Sharp & Dohme
Publication of CL2022000329A1 publication Critical patent/CL2022000329A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención proporciona métodos para el tratamiento contra la malaria que comprende la administración de compuestos de la Fórmula (I’): (I’) o una sal de este farmacéuticamente aceptable, a un sujeto que lo necesite, en donde las variables son como se definen en la presente. La invención también proporciona usos de los compuestos de la Fórmula (I), como se define en la presente, para inhibir la actividad de plasmepsina X, plasmepsina IX o plasmepsina X y IX, para el tratamiento contra la infección de Plasmodium, y para el tratamiento contra la malaria. También se proporcionan métodos de tratamiento que comprenden además la administración de uno o más compuestos antipalúdicos.
CL2022000329A 2019-08-15 2022-02-08 Agentes antipalúdicos. CL2022000329A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2019/100781 WO2021026884A1 (en) 2019-08-15 2019-08-15 Antimalarial agents

Publications (1)

Publication Number Publication Date
CL2022000329A1 true CL2022000329A1 (es) 2022-10-07

Family

ID=74570489

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022000329A CL2022000329A1 (es) 2019-08-15 2022-02-08 Agentes antipalúdicos.

Country Status (20)

Country Link
US (1) US20220331321A1 (es)
EP (1) EP4013742A4 (es)
JP (1) JP7116859B2 (es)
KR (1) KR20220047312A (es)
CN (1) CN114555564B (es)
AR (1) AR119784A1 (es)
AU (1) AU2020328678B2 (es)
BR (1) BR112022002692A2 (es)
CA (1) CA3147665C (es)
CL (1) CL2022000329A1 (es)
CO (1) CO2022001342A2 (es)
CR (1) CR20220067A (es)
DO (1) DOP2022000037A (es)
EC (1) ECSP22011746A (es)
IL (1) IL290525A (es)
JO (1) JOP20220038A1 (es)
MX (1) MX2022001768A (es)
TW (1) TW202115041A (es)
UA (1) UA128074C2 (es)
WO (2) WO2021026884A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023102747A1 (en) * 2021-12-07 2023-06-15 Merck Sharp & Dohme Llc Antimalarial agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) * 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
UA108363C2 (uk) * 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
CN108290860B (zh) * 2015-11-25 2021-08-10 Ucb生物制药有限责任公司 作为plasmepsin v抑制剂的亚氨基四氢嘧啶酮衍生物
EP3416647A4 (en) * 2016-02-18 2019-10-23 Merck Sharp & Dohme Corp. N3-SUBSTITUTED IMINOPYRIMIDINONES AS ANTIMALARIAL AGENTS
GB201603104D0 (en) * 2016-02-23 2016-04-06 Ucb Biopharma Sprl Therapeutic agents
GB201906804D0 (en) * 2019-05-14 2019-06-26 Ucb Biopharma Sprl Therapeutic agents
WO2021155612A1 (en) * 2020-02-09 2021-08-12 Merck Sharp & Dohme Corp. Antimalarial agents

Also Published As

Publication number Publication date
JP7116859B2 (ja) 2022-08-10
AR119784A1 (es) 2022-01-12
WO2021027502A1 (en) 2021-02-18
AU2020328678B2 (en) 2023-02-02
ECSP22011746A (es) 2023-01-31
CN114555564B (zh) 2024-01-30
BR112022002692A2 (pt) 2022-09-27
UA128074C2 (uk) 2024-03-27
CA3147665A1 (en) 2021-02-18
WO2021026884A1 (en) 2021-02-18
CN114555564A (zh) 2022-05-27
JP2022534454A (ja) 2022-07-29
EP4013742A1 (en) 2022-06-22
IL290525A (en) 2022-04-01
MX2022001768A (es) 2022-06-09
CR20220067A (es) 2022-04-20
CA3147665C (en) 2023-11-28
DOP2022000037A (es) 2022-06-30
CO2022001342A2 (es) 2022-05-20
AU2020328678A1 (en) 2022-03-03
JOP20220038A1 (ar) 2023-01-30
EP4013742A4 (en) 2023-07-12
KR20220047312A (ko) 2022-04-15
TW202115041A (zh) 2021-04-16
US20220331321A1 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
CO2018010748A2 (es) Agentes antivirales contra la hepatitis b
CO2019000069A2 (es) Agentes antivirales contra la hepatitis b
CO2021015067A2 (es) Compuestos antivirales que contienen nitrilo
CL2023001738A1 (es) Inhibidores de prmt5
NI202000101A (es) Compuestos antagonistas de pcsk9
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
WO2017142825A3 (en) N3-substituted iminopyrimidinones as antimalarial agents
UY37998A (es) Agentes antivirales contra la hepatitis b
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
CR20140086A (es) Tratamientos de combinación para hepatitis c
DOP2015000169A (es) Compuestos tetracíclicos sustituidos con heterociclo y usos de los mismos para el tratamiento de enfermedades víricas
UY39559A (es) Compuestos y su uso
CR20220553A (es) Pirrolopirimidinaminas como inhibidores del sistema del complemento
ECSP19026973A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
AR128500A1 (es) Inhibidores de arn helicasa dhx9 y usos de los mismos
CL2022000329A1 (es) Agentes antipalúdicos.
RU2017134285A (ru) Борсодержащие низкомолекулярные соединения как антипротозойные агенты
AR067446A1 (es) Un medicamento para tratar higado graso que comprende cilostazol
CL2022000781A1 (es) Tratamientos cognitivos medicinales
TR201910158T4 (tr) İmmün hastalıklara yönelik önleyici ve/veya terapötik ajan.
AR125479A1 (es) Inhibidores de il4i1 y métodos de uso
DOP2024000108A (es) Agentes contra el paludismo
AR124136A1 (es) Nuevos compuestos orgánicos
CO2023017669A2 (es) Terapia combinada anti-vhc ventajosa